FIGURE 5.

COX-2 inhibitor and EP3 receptor antagonist enhance GSIS in primary mouse islets isolated from WT but not GX sPLA₂-deficient mice. A, 25 islets isolated from 3-month-old WT and GX KO mice (n = 4 mice per group) were treated with the COX-2 inhibitor, NS398 (10 μm) or an equivalent volume of vehicle (DMSO) in regular culture medium containing 1% FBS for 20 h (n = 4) prior to assaying GSIS as described under “Experimental Procedures.” B, GSIS assay was performed as described under “Experimental Procedures” in 25 primary islets isolated from WT and GX KO mice (n = 4) with either the EP3 antagonist, L-798,106 (10 μm) or an equivalent volume of vehicle in the assay buffer. NS398 and L-798,106 treatment did not alter insulin secretion from either WT or GX KO islets under basal conditions. Data are presented as mean ± S.E.; *, p < 0.05; **, p < 0.01.